![Andrew R. de Guttadauro](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Andrew R. de Guttadauro
Präsident bei Oncolytics Biotech (U.S.), Inc.
Vermögen: 11 037 $ am 31.05.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Kirk Look | M | - |
Oncolytics Biotech (U.S.), Inc.
![]() Oncolytics Biotech (U.S.), Inc. Pharmaceuticals: MajorHealth Technology Oncolytics Biotech (US), Inc. is based in Half Moon Bay, CA. Part of Oncolytics Biotech, Inc., Oncolytics Biotech (US), Inc. is a company that manufactures pharmaceutical products. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Ronald B. Moss | M | 64 |
Vical, Inc.
![]() Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 3 Jahre |
Mary Ann Dillahunty | F | - |
Oncolytics Biotech (U.S.), Inc.
![]() Oncolytics Biotech (U.S.), Inc. Pharmaceuticals: MajorHealth Technology Oncolytics Biotech (US), Inc. is based in Half Moon Bay, CA. Part of Oncolytics Biotech, Inc., Oncolytics Biotech (US), Inc. is a company that manufactures pharmaceutical products. | - |
Richard Kenney | M | 66 |
Vical, Inc.
![]() Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 3 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 4 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Andrew R. de Guttadauro
- Persönliches Netzwerk